NEW YORK, March 30 (GenomeWeb News) - Clinomics has licensed its Oncology Cell Signalling Database to AstraZeneca, the company's parent, Cytomyx holdings, said today.
The searchable database includes over 30,000 tissue samples from different forms of human cancer, and protein expression of 100 cell signaling proteins across all of these samples, the company said. It allows companies to biologically characterize gene and protein targets in numerous diseases, through searching numerous data fields including medical history, pathology, demographics, and treatment outcomes.
Under the non-exclusive agreement, AstrZeneca has obtained multiple user licenses to the database.
Cytomyx, of Cambridge, UK, acquired Clinomics in December 2003.